Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:
- Unique arrangement structures at specific product life cycle stages
- Protecting IP
- Avoiding short-term fallout
- The impact of collaboration on future growth and exit strategies
- Strategies from both sides of the agreement: increasing the opportunity for future collaborations
Panelist:
- Richard A. Kaufman, Partner, Foley & Lardner LLP
- David Webb, Vice President, Research & Site Director, Celgene
- David J. Weitz, Senior Vice President, General Counsel and Chief Intellectual Property Counsel, Takeda Pharmaceuticals
- Linda Pullan, Ph.D., Pullan Consulting
Related Insights
June 20, 2025
Foley Career Perspectives
Foley Juneteenth Program: Exploring the Hidden History to Further Our Mutual Understanding
In celebration of Juneteenth, Foley & Lardner welcomed Dr. Deirdre Cooper Owens, author and historian, for a firmwide virtual program on…
July 10, 2025
Events
Mandatory Roth Catch-up
Join Foley’s upcoming webinar on mandatory Roth catch-up contributions effective January 1, 2026. Learn how the new rules impact high earners, what guidance exists, and practical tips for plan compliance.
June 20, 2025
Foley Viewpoints
Federal Court Enjoins Former Franchisees and Two Related Entities from Competing Against Franchisor
A federal court recently granted in part and denied in part a franchisor’s motion to enjoin the post-termination activities of its former…